Rapid Detection of D-dimer Using a Fiber Optic Biosensor

Chris A. Rowe; Jeni S. Bolitho; Andrew Jane; Peter G. Bundesen; Dennis B. Rylatt; Paul R. Eisenberg; Frances S. Ligler

doi:10.1055/s-0037-1614227

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1998; 79(01): 94-98
DOI: 10.1055/s-0037-1614227

Review Article

Schattauer GmbH

Rapid Detection of D-dimer Using a Fiber Optic Biosensor

Chris A. Rowe

¹Naval Research Laboratory, Center for Bio/Molecular Science and Engineering, Washington, DC, USA

,

Jeni S. Bolitho

²AGEN Biomedical Ltd., Acacia Ridge, QLD, Australia

,

Andrew Jane

²AGEN Biomedical Ltd., Acacia Ridge, QLD, Australia

,

Peter G. Bundesen

²AGEN Biomedical Ltd., Acacia Ridge, QLD, Australia

,

Dennis B. Rylatt

²AGEN Biomedical Ltd., Acacia Ridge, QLD, Australia

,

Paul R. Eisenberg

³Cardiovascular Division, Washington University School of Medicine, St. Louis, MO, USA

,

Frances S. Ligler

¹Naval Research Laboratory, Center for Bio/Molecular Science and Engineering, Washington, DC, USA

› Institutsangaben

Abstract

Summary

We describe a rapid and sensitive method for detection and quantification of D-dimer and other crosslinked fibrin degradation products (XL-FDPs), which are present in elevated concentrations in patients with sepsis and thrombotic disorders. The method utilizes a sandwich fluoroimmunoassay immobilized in the sensing region of an evanescent wave biosensor. Physiological concentrations of D-dimer and high molecular weight XL-FDP could be determined in buffer and plasma samples on calibrated fibers in 11 min. Samples from septic patients were assayed using ELISA and the fiber optic method; concentrations determined by fiber optic assay were strongly correlated with those determined by ELISA (r = 0.918); intra- and inter-assay errors were comparable to those from ELISAs. Given its accuracy and rapid response time, this fiber optic biosensor shows great potential for development as a diagnostic tool.

Volltext

Referenzen

References
1 Francis CW, Marder VJ. A molecular model of plasmic digestion of cross-linked fibrin. Semin Thromb Haemostas 1982; 8: 25-35.
2 Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980; 43: 77-89.
3 Chen R, Doolittle RF. γ-γ Cross-linking sites in human and bovine fibrin. Biochem 1971; 10: 4486-91.
4 Whitaker AN, Elms MJ, Masci PP, Bundesen PG, Rylatt DB, Webber AJ, Bunce IH. Measurement of crosslinked fibrin derivatives in plasma: An immunoassay using monoclonal antibodies. J Clin Pathol 1984; 37: 882-7.
5 Wilde JT, Kitchen S, Kinsey S, Greaves M, Preston FE. Plasma D-dimer levels and their relationship to serum fibrinogen/fibrin degradation products in hypercoagulable states. Brit J Haem 1989; 71: 65-70.
6 John MA, Elms MJ, O’Reilly EJ, Rylatt DB, Bundesen PG, Hillyard CJ. The SimpliRED D dimer test: A novel assay for the detection of crosslinked fibrin degradation products in whole blood. Thromb Res 1990; 58: 273-81.
7 Elms MJ, Bundesen PG, Rowbury D, Goodall SF, Wakeham N, Rowell JA, Hillyard CJ, Rylatt DB. Automated determination of cross-linked fibrin derivatives in plasma. Blood Coag Fibrinol 1993; 4: 159-64.
8 Hart R, Bate I, Dinh D, Elms M, Bundesen P, Hillyard C, Rylatt DB. The detection of D-dimer in plasma by enzyme immunoassay: Improved discrimination is obtained with a more specific signal antibody. Blood Coag Fibrinol 1994; 5: 227-32.
9 Lip GYP, Rumley A, Dunn FG, Lowe GDO. Plasma fibrinogen and fibrin D-dimer in patients with atrial fibrillation: Effects of cardioversion to sinus rhythm. Int J Cardiol 1995; 51: 245-51.
10 Francis CW, Connaghan DG, Marder VJ. Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction. Circulation 1986; 74: 1027-36.
11 Eisenberg PR, Sherman LA, Perez J, Jaffe AS. Relationship between elevated plasma levels of crosslinked fibrin degradation products (XL-FDP) and the clinical presentation of patients with myocardial infarction. Thromb Res 1987; 46: 109-20.
12 Enderson BL, Chen JP, Robinson R, Maull KI. Fibrinolysis in multisystem trauma patients. J Trauma 1991; 31: 1240-6.
13 Engelman DT, Gabram SGA, Allen L, Ens GE, Jacobs LM. Hypercoagulability following multiple trauma. World J Surg 1996; 20: 5-10.
14 Hafter R, Schrock R, von Hugo R, Graeff H. Measurement of crosslinked fibrin derivatives in plasma and ascitic fluid with monoclonal antibodies against D dimer using EIA and latex test. Scand J Clin Lab Invest 1985; 45 (Suppl. 178) 137-44.
15 Gabazza EC, Taguchi O, Yamakami T, Machisi M, Ibata H, Tsutsui K, Suzuki S. Coagulation-fibrinolysis system and markers of collagen metabolism in lung cancer. Cancer 1992; 70: 2631-6.
16 Gordge MP, Faint RW, Rylance PB, Ireland H, Lane DA, Neild GH. Plasma D dimer: A useful marker of fibrin breakdown in renal failure. Thromb Haemost 1989; 61: 522-5.
17 Omran SA, El-Bassiouni NE, Hussein NA, Akl MM, Hussein AT, Mohamed AA. Disseminated intravascular coagulation in endemic hepatosplenic schistosomiasis. Haemostasis 1995; 25: 218-28.
18 Trofatter KF, Howell MC, Greenberg CS, Hage ML. Use of the fibrin D-dimer in screening for coagulation abnormalities in pre-eclampsia. Obstet Gynecol 1989; 73: 435-9.
19 Trofatter KF, Trofatter MO, Caudle MR, Offutt DQ. Detection of fibrin D-dimer in plasma and urine of pregnant women using Dimertest latex assay. South Med J 1993; 86: 1017-21.
20 Paternoster DM, Stella A, Simioni P, Mussap M, Pelbani M. Coagulation and plasma fibronectin parameters in HELLP syndrome. Int J Gynecol Obstet 1995; 50: 263-8.
21 Graeff H, Hafter R. Clinical aspects of fibrinolysis. In: Haemostasis and Thrombosis. Bloom HL, Thomas DP. eds. Churchill Livingstone; Edinburgh, UK: 1987. pp. 245-54.
22 Deitcher SR, Eisenberg PR. Elevated concentrations of cross-linked fibrin degradation products in plasma: An early marker of Gram-negative bacteremia. Chest 1993; 103: 1107-12.
23 Takahashi H, Takizawa S-I, Hakano M, Tatewaki W, Nagasaki Y, Sasagawa Y, Shibata A. Evaluation of fibrinolytic therapy by measuring cross-linked fibrin derivatives and plasmin-alpha 2- antiplasmin inhibitor complex in plasma. Tohoku J Exp Med 1987; 153: 295-302.
24 Eisenberg PR, Sobel BE, Jaffe AS. Characterization in vivo of the fibrin specificity of activators of the fibrinolytic system. Circulation 1988; 78: 592-7.
25 Faivre R, Mirshahi M, Ducellier D, Soria C, Soria J, Mirshahi M, Kieffer Y, Bassand JP, Caen J, Maurat JP. Evolution of plasma specific degradation products during thrombolytic therapy in patients with thrombo-embolism. Thromb Res 1988; 50: 583-9.
26 Rylatt DB, Blake AS, Cottis LE, Massingham DA, Fletcher WA, Masci PP, Whitaker AN, Elms M, Bunce I, Webber AJ, Wyatt D, Bundesen PG. An immunoassay for human D dimer using monoclonal antibodies. Thromb Res 1983; 31: 767-78.
27 Savage D, Mattson G, Desai S, Nielander G, Morgensen S, Conklin E. Avidin-Biotin Chemistry: A Handbook. Pierce; Rockford, IL: 1992
28 Anderson GP, Golden JP, Ligler FS. A fiber optic biosensor: Combination tapered fibers designed for improved signal acquisition. Biosens Bioelectron 1993; 8: 249-56.
29 Ligler FS, Golden JP, Shriver-Lake LC, Ogert RA, Wijesuria D, Anderson GP. Fiber-optic biosensor for the detection of hazardous materials. Immunometh 1993; 3: 122-7.
30 Bhatia SK, Shriver-Lake LC, Prior KJ, Georger JH, Calvert JM, Bredehorst R, Ligler FS. Use of thiol-terminal silanes and heterobifunctional crosslinkers for immobilization of antibodies on silica surfaces. Anal Biochem 1989; 178: 408-13.
31 Ligler FS, Calvert J, Georger J, Shriver-Lake L, Bhatia S. A method for attaching functional proteins to silica surfaces. 1991 US Patent No. 5,077,210.
32 Golden JP, Anderson GP, Ogert RA, Breslin KA, Ligler FS. An evanescent wave fiber optic biosensor: Challenges for real world sensing. SPIE 1992; 1796: 2-8.
33 Golden JP, Saaski EW, Shriver-Lake LC, Anderson GP, Ligler FS. A portable multichannel fiber optic biosensor for field detection. Opt Eng 1997; 36: 1008-13.
34 Graeff H, Hafter R, Bachmann L. Subunit and macromolecular structures of circulating fibrin from obstetric patients with intravascular coagulation. Thromb Res 1979; 16: 313-28.
35 Graeff H, Hafter R. Detection and relevance of crosslinked fibrin derivatives in blood. Semin Thromb Haemostas 1982; 8: 57-68.
36 Gaffney PJ, Creighton LJ, Callus M, Thorpe R. Monoclonal antibodies to cross-linked fibrin degradation products (XL-FDP) II. Evaluation in a variety of clinical conditions. Brit J Haematol 1988; 68: 91-6.
37 Feldman SF, Uzgiris EE, Penney CM, Gui JY, Shu EY, Stokes EB. Evanescent wave immunoprobe with high bivalent antibody activity. Biosens Bioelectron 1995; 10: 423-34.
38 Shibata T, Magari Y, Kamberi P, Ishii T, Tomo T, Yasumori R, Nasu M. Significance of urinary fibrin/fibrinogen degradation products (FDP) D-dimer measured by a highly sensitive ELISA method with a new monoclonal antibody (D-D E72) in various renal diseases. Clin Nephrol 1995; 44: 91-5.
39 Bounameaux H, de Moerloose P, Perrier A, Reber G. Plasma measurement of D-dimer as diagnostic aid in suspected venous thromboembolism: An overview. Thromb Haemost 1994; 71: 1-6.
40 Ellis DR, Eaton AS, Plank MC, Butman BT, Ebert RF. A comparative evaluation of ELISAs for D-dimer and related fibrin(ogen) degradation products. Blood Coag Fibrinol 1993; 4: 537-49.
41 Lawler CM, Bovill EG, Stump DC, Collen DJ, Mann KC, Tracy RP. Utility of specific laboratory markers of fibrinolysis in the thrombolysis of Myocardial Infarction Trial, phase I (abstract). Circulation. 1988 78. (suppl II) II-231.
42 Eisenberg PR, Jaffe AS, Stump DC, Collen D, Bovill EG. Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis. Circulation 1990; 82: 1159-68.